Ultralife (ULBI) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
The annual meeting is scheduled for July 16, 2025, in Atlanta, GA, with voting available online, by phone, or by mail.
Proxy materials are distributed primarily via the internet to reduce costs and environmental impact.
Only shareholders of record as of May 22, 2025, are entitled to vote.
Forward-looking statements regarding environmental and social goals are included, subject to risks and uncertainties.
Voting matters and shareholder proposals
Shareholders will vote to elect five directors for a one-year term and to ratify the selection of Freed Maxick P.C. as the independent auditor for 2025.
Proposals require a plurality or majority of shares present to pass, with specific rules for abstentions and broker voting.
Shareholder proposals for the 2026 meeting must be received by January 28, 2026, for inclusion.
Board of directors and corporate governance
The board consists of five nominees, with a mix of industry, financial, and executive experience.
All directors except the CEO are independent per NASDAQ standards; the board chair is separate from the CEO.
Three standing committees: Audit and Finance, Corporate Development and Governance, and Compensation and Management.
Directors are subject to retirement age policies and stock ownership guidelines.
Procedures exist for stockholder recommendations for director nominations, emphasizing diversity and relevant expertise.
Latest events from Ultralife
- Q4 revenue up 10.6% year-over-year; impairment led to net loss, but backlog and new products support 2026 growth.ULBI
Q4 202510 Mar 2026 - Q2 revenue up 13% to $48.6M, but margins and net income declined; outlook for H2 is positive.ULBI
Q2 20253 Feb 2026 - Record segment sales, margin gains, and major debt reduction highlight Q2 2024.ULBI
Q2 20243 Feb 2026 - Q3 revenue and profit declined, but debt reduction and a $50M acquisition set up future growth.ULBI
Q3 202415 Jan 2026 - Q4 revenue was $43.9M, with Electrochem acquisition and strong backlog driving 2025 growth.ULBI
Q4 202424 Dec 2025 - Vote on director elections and auditor ratification at the July 16, 2025 annual meeting.ULBI
Proxy Filing1 Dec 2025 - Q1 2025 revenue up 21% to $50.7M, but net income and margins declined on higher costs.ULBI
Q1 202526 Nov 2025 - Q3 2025 revenue up 21.5% to $43.4M, but net loss of $1.22M on lower margins and one-time costs.ULBI
Q3 202519 Nov 2025